Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 90 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Quick Bolus Clear all
Recruiting Phase 3 Interventional

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

NCT06376916
View directory record Official record
Conditions
Tachycardia Atrial, Atrial Fibrillation, Atrial Flutter With Rapid Ventricular Response
Interventions
Magnesium Sulfate 2 G, Magnesium Sulfate 4 G, Saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 3 Interventional Results available

Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation

NCT01528891
View directory record Official record
Conditions
Tonsillectomy
Interventions
Dexmedetomidine, Placebo
Drug · Other
Lead sponsor
Peter Davis
Other
Eligibility
4 Years to 10 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 3 Interventional

Pediatric Diabetics Type 1 Using InsuPatch

NCT01368978
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
InsuPatch
Device
Lead sponsor
Insuline Medical Ltd.
Industry
Eligibility
12 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 28, 2026, 10:24 AM EDT
Not listed Phase 3 Interventional

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

NCT05799248
View directory record Official record
Conditions
Prostate Cancer
Interventions
rhPSMA-7.3 (18F)
Drug
Lead sponsor
MidLantic Urology
Other
Eligibility
18 Years and older · Male only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bala-Cynwyd, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Results available

Intubation Conditions Achieved With Rapid Co-administration of Rocuronium and Propofol Versus Classical Induction

NCT05509192
View directory record Official record
Conditions
Anesthesia
Interventions
MTPI, Classic Induction
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Results available

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

NCT03336528
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Degludec, Glargine, Aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Results available

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

NCT02455076
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide, Glargine, Rapid-acting insulin analogs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Preprandial Ghrelin Effect

NCT02913703
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Ghrelin, Saline
Drug · Other
Lead sponsor
Jenny Tong, MD, MPH
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sympathetic Activation in Obesity

NCT04946552
View directory record Official record
Conditions
Obesity, Healthy
Interventions
PET Scan, Mixed Meal Test, Muscle sympathetic nerve activity (MSNA), Oral Glucose Tolerance Test, Body Composition, Percent Body Fat & Percent Body Water (Tanita scale), CT Scan, Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)
Diagnostic Test · Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2024 · Synced Oct 28, 2026, 10:24 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects

NCT04699747
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
F-18 3F4AP
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 10:24 AM EDT
Recruiting Phase 1 Interventional

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

NCT04689048
View directory record Official record
Conditions
Brain Metastases, Adult, Brain Metastases, Brain Cancer
Interventions
18F fluciclovine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 28, 2026, 10:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Arterial Stiffness in Type I Diabetes Mellitus

NCT02218268
View directory record Official record
Conditions
Arterial Stiffness in Youth With Type 1 Diabetes
Interventions
Pre-meal bolus, No meal bolus
Drug
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Not applicable Interventional Results available

Evaluation of The Postprandial Impact of Automated Priming Bolus for Full Closed Loop Insulin Delivery

NCT05528770
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
FCL+BPS, FCL
Device
Lead sponsor
Marc Breton
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 28, 2026, 10:24 AM EDT
Active, not recruiting Early Phase 1 Interventional

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

NCT03164486
View directory record Official record
Conditions
Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Metastatic Malignant Neoplasm in the Breast, Metastatic Malignant Neoplasm in the Colon, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Rectum, Pancreatic Carcinoma
Interventions
18F-αvβ6-BP
Drug
Lead sponsor
Julie L. Sutcliffe, Ph.D
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 28, 2026, 10:24 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Prevention of Postop Atrial Fibrillation Through Intraoperative Inducibility of Atrial Fibrillation and Amiodarone Treatment

NCT03868150
View directory record Official record
Conditions
Postoperative Atrial Fibrillation
Interventions
Amiodarone Injection, Intraoperative Rapid Atrial Pacing
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2050
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Results available

Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma

NCT01411852
View directory record Official record
Conditions
Blunt Trauma, Penetrating Wound, Hemorrhagic Shock
Interventions
0.9% Sodium Chloride 250 mL bolus, 0.9% Sodium Chloride 2000 mL bolus
Drug
Lead sponsor
University of Washington
Other
Eligibility
15 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Birmingham, Alabama • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Not applicable Interventional Results available

Pilot Study to Evaluate Safety, Tolerability, and Performance of the FAST PV Technology™ in Chronic Dialysis Patients

NCT04733664
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
VFI using the FAST PV Technology
Device
Lead sponsor
FAST BioMedical
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Results available

Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson

NCT01779869
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Regadenoson
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Results available

Glargine U300 Hospital Trial

NCT03013985
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Glargine U300, Glargine U100, Glulisine Insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 3 Interventional

Using Vasopressor Medication to Support Blood Pressure During Intubation Procedure

NCT05355974
View directory record Official record
Conditions
Respiratory Failure, Hypotension and Shock, Hypotension on Induction, Intubation Complication, Anesthesia Intubation Complication
Interventions
Norepinephrine, Lactated Ringers, Intravenous, normal saline, Plasma-lyte
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 28, 2026, 10:24 AM EDT
Withdrawn Phase 3 Interventional

A Study to Decrease Suicidal Thinking Using Ketamine

NCT02418702
View directory record Official record
Conditions
Depression, Suicide
Interventions
0.2 mg/kg ketamine, placebo
Drug · Other
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Oct 28, 2026, 10:24 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression

NCT02378415
View directory record Official record
Conditions
Acute Depression
Interventions
Ketamine, Placebo
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Not applicable Interventional

Improving the Concentration of MR Contrast in the Arteries

NCT02155218
View directory record Official record
Conditions
Magnetic Resonance Angiography, Contrast Media
Interventions
Standard Injection Rate, Patient Tailored Injection Rate, gadolinium contrast
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 28, 2026, 10:24 AM EDT
Not listed Phase 4 Interventional

Rapid Atrial Fibrillation Treatment Strategy

NCT04092621
View directory record Official record
Conditions
New Onset Atrial Fibrillation, Sepsis, Respiratory Failure
Interventions
Amiodarone in Parenteral Dosage Form, Amiodarone Pill, Direct Current Cardioversion (DCC), Rate-control therapy
Drug · Procedure
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 28, 2026, 10:24 AM EDT